References:
1. Weekly Hospitalization Trends - Johns Hopkins Coronavirus Resource Center. Johns Hopkins Coronavirus Resource Center.
2. Johns Hopkins Coronavirus Resource Center. Johns Hopkins Coronavirus Resource Center.
3. Ritchie H ME, Rodés-Guirao L et al. Coronavirus Pandemic (COVID-19). Our World in Data.
4. Ahmad FB CJ, Miniño A, Anderson RN Provisional Mortality Data — United States, 2020 MMWR Morb Mortal Wkly Rep 2021;70:519–522.70:519-22.
5. COVID Data Tracker. Centers for Disease Control and Prevention.
6. Monitoring of COVID-19 Infection In Lebanon - 12/4/2022.
7. aPetrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. Bmj. 2020;369:m1966; bUnderlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. Centers for Disease Control and Prevention; cLiang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Internal Medicine. 2020;180(8):1081-9; dCariou B, Pichelin M, Goronflot T, Gonfroy C, Marre M, Raffaitin-Cardin C, et al. Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: Results from the CORONADO study. Diabetes Res Clin Pract. 2021;175:108695.
8. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clin Infect Dis. 2021;73(12):2257-64.
9. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020.
10. Lloyd EC, Gandhi TN, Petty LA. Monoclonal Antibodies for COVID-19. JAMA. 2021;325(10):1015-.
11. Fact Sheet for Healthcare Providers Emergency Use Authorization (EUA) of Sotrovimab. U.S. Food and Drug Administration (FDA).
12. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021;385(21):1941-50.
13. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447-56.e11.
14. Zahreddine NK, Haddad SF, Kerbage A, Kanj SS. Challenges of coronavirus disease 2019 (COVID-19) in Lebanon in the midst of the economic collapse. Antimicrobial Stewardship & Healthcare Epidemiology. 2022;2(1):e67.
15. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. 2022. .
16. Saheb Sharif-Askari F, Ali Hussain Alsayed H, Tleyjeh I, Saheb Sharif-Askari N, Al Sayed Hussain A, Saddik B, et al. Sotrovimab lowers the risk of COVID-19 related hospitalization or death in a large population cohort in the United Arab Emirates. Clin Pharmacol Ther. 2022.
17. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. 2022;22(5):622-35.
18. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Internal Medicine. 2020;180(11):1436-47.
19. Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, et al. Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. medRxiv. 2022.
20. Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncology. 2022;8(1):69-78.
21. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-7.
22. Nader Marta G, Colombo Bonadio R, Nicole Encinas Sejas O, Watarai G, Mathias Machado MC, Teixeira Frasson L, et al. Outcomes and Prognostic Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19. JCO Global Oncology. 2021(7):1084-92.